Anti-OCIAD1 Antibody

OCIAD1 was identified via immunoscreening of an ovarian carcinoma cDNA library from ovarian cancer patients and is expressed in multiple tissues including ovary, placenta, brain, testis, prostate, and mammary gland. Two isoforms of OCIAD1 are known to exist; the shorter isoform is restricted to the central nervous system. OCIAD1 is a transmembrane protein whose overexpression in HEY ovarian cancer cells increased lysophosphatidic acid- (LPA-) induced, but not basal level cell adhesion to extracellular matrix proteins collagen I and laminin10/11. This adhesion is not blocked by LY294002 and GF109203X, suggesting that OCIAD1 does not use protein kinase C and PI3 kinase signaling pathways to exert its effect on adhesion.

OCIAD1 antibody was raised against a 16 amino acid synthetic peptide from near the carboxy terminus of human OCIAD1. The immunogen is located within the last 50 amino acids of OCIAD1.

Isoform 1 is highly expressed in many tissues, including testis, brain, placenta, ovary, prostate and mammary gland. Isoform 2 expression is restricted to the central nervous system including brain, cerebellum and spinal cord.

Maintains stem cell potency (By similarity) . Increases STAT3 phosphorylation and controls ERK phosphorylation (By similarity) . May act as a scaffold, increasing STAT3 recruitment onto endosomes (By similarity) . Involved in integrin-mediated cancer cell adhesion and colony formation in ovarian cancer (PubMed:20515946) .

OCIAD1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.